Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung disease

检查炎症小体以确定进行性间质性肺疾病的生物标志物

基本信息

批准号：
10375577
负责人：
Justin M Oldham
金额：
$ 7.85万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-01 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10375577
关键词：
Address B-Lymphocytes Biological Markers California Cell surface Cessation of life Chronic Clinical Clinical Data Clinical Trials Connective Tissue Diseases Data Derivation procedure Development Diffuse Disease Disease Progression Equilibrium Extrinsic allergic alveolitis Fibrosis Foundations Funding Goals Immune Immunosuppressive Agents Inflammasome Inflammation Inflammatory Interleukins Interstitial Lung Diseases Investigation K-Series Research Career Programs Knowledge Modeling Molecular Profiling National Heart, Lung, and Blood Institute Natural History Outcome Patient Monitoring Patients Phenotype Plasma Population Process Proteins Proteomics Pulmonary Fibrosis Quality of life Research Sampling Testing Texas Therapeutic Intervention Therapeutic immunosuppression Universities Validation Vital capacity Work antifibrotic treatment biomarker development chemokine clinical biomarkers clinical decision support clinical decision-making cohort cytokine diagnostic tool disease phenotype fibrotic interstitial lung disease hazard high risk migration molecular diagnostics novel optimal treatments patient population patient subsets precision medicine pulmonary function decline response tool treatment response treatment strategy

项目摘要

Project Summary Interstitial lung disease (ILD) comprises a diverse group of diffuse parenchymal disorders with variable degrees of inflammation and fibrosis. Among the most common fibrosing ILDs with preceding inflammation are chronic hypersensitivity pneumonitis (CHP) and connective tissue disease-associated ILD (CTD-ILD). Substantial proportions of patients with CHP and CTD-ILD develop a progressive phenotype, which negative impacts survival and quality of life. Both conditions are generally treated with immunosuppressive therapy and may now also benefit from anti-fibrotic therapy. Because some patients will remain stable without therapy, there exists a critical need to more reliably identify CHP and CTD-ILD patients that will develop progressive ILD and define an optimal treatment strategy for such patients. This proposal seeks to address this gap in knowledge by employing a proteomic approach to identify inflammatory proteins predictive of progressive ILD and differential immunosuppressant response in patients with CHP and CTD-ILD. This proposal will lay the foundation for subsequent targeted protein investigation that will facilitate the development of biomarkers to guide clinical decision making in this patient population.

项目摘要间质性肺疾病（ILD）包括一组不同的弥漫性实质性疾病炎症和纤维化程度。在前面发炎的最常见的纤维化ILD中是慢性超敏性肺炎（CHP）和结缔组织疾病相关的ILD（CTD-ILD）。 CHP和CTD-ILD患者的大量比例发展出一种进行性表型，为阴性影响生存和生活质量。两种疾病通常通过免疫抑制治疗和现在可能还可以从抗纤维化疗法中受益。因为有些患者在没有治疗的情况下会保持稳定，所以存在迫切需要更多可靠地识别CHP和CTD-ILD患者 ILD并为此类患者定义最佳治疗策略。该建议旨在解决此差距通过采用蛋白质组学方法来鉴定炎症蛋白来预测进行性ILD的知识 CHP和CTD-ILD患者的免疫抑制剂反应差异。该提议将提出随后的靶向蛋白质研究基金会，将有助于生物标志物的发展指导该患者人群的临床决策。